Electrical dyssynchrony mapping and optimization of nonresponders in patients programmed with the adaptive cardiac resynchronization therapy algorithm

Heart Rhythm 2024

View Full Publication

Cardiac resynchronization therapy optimization in nonresponders and incomplete responders using electrical dyssynchrony mapping


Alan J. Bank, MD; Kevin V. Burns, PhD; Christopher D. Brown, BA; Evan Walser-Kuntz, MS; Madeline A. Czeck, PhD; Robert G. Hauser, MD1; Jay D. Sengupta, MD


Abstract


Background


The adaptive cardiac resynchronization therapy (CRT) (aCRT) algorithm provides an important clinical benefit. However, a significant number of patients are nonresponders.


Objectives


The goals of this study were to quantify electrical synchrony in patients programmed with aCRT and to assess the echocardiographic effects of optimization in CRT nonresponders and incomplete responders.


Methods


We studied 125 patients programmed with aCRT and measured electrical synchrony at multiple device settings using novel electrical dyssynchrony mapping (EDM) technology. Electrical synchrony was quantified as cardiac resynchronization index (CRI), a measure that analyzes areas between multiple pairs of anterior and posterior electrograms and calculates synchrony normalized to native rhythm.


Results


CRI improved from baseline aCRT settings to optimal settings on the basis of EDM (56%±29% vs 92%±12%; P<.001). Patients programmed with left ventricle (LV)–only aCRT (group 1, n=68 [54%]) had a higher CRI (62%±25% vs 48%±31%; P=.014) than did patients programmed with biventricular aCRT (group 2, n=57 [46%]). In group 1 and group 2, optimal CRI during sequential biventricular (92%±13% and 93%±9%, respectively) and LV-only (92%±6% and 91%±7%, respectively) pacing was significantly (P<.001) higher than CRI at baseline aCRT setting. In a subset of 53 nonresponders optimized using EDM, there were significant improvements in CRI (37%±25%; P<.0001), LV ejection fraction (6.2%±6.6%; P<.0001), end-diastolic volume (9.5±28.2 mL; P=.015), end-systolic volume (13.4±24.9 mL; P<.001), and transverse (1.5%±4.4%; P=.014), longitudinal (1.0%±2.5%; P=.003), and circumferential (2.6%±8.5%; P=.047) strain.


Conclusion


Electrical synchrony improves 56% with CRT using aCRT programming and 92% with EDM optimization. Optimization of aCRT-programmed nonresponders results in significant improvements in LV size and systolic function, offering the possibility of converting CRT nonresponders into responders.


Elevate heart failure therapy for all CRT patients.

Connect to explore engaging with Myochron on its journey to help patients, providers, and health systems elevate the standard of care, while reducing the burden of non-response.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.

*The Myochron product is currently under development and has not been approved by regulatory authorities such as the FDA or other equivalent bodies outside the US. It is not available for sale, distribution, or commercial use at this time. The information provided on this website is for informational purposes only and should not be construed as medical advice, diagnosis, or treatment. Please consult with a qualified healthcare professional for any medical concerns or questions.

Subscribe to be in touch with latest updates & news.

©Myochron 2024.